Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, with a rise of nearly 13% in the afternoon and a cumulative increase of over 130% in the past two weeks, reflecting strong market interest and strategic developments [1] Group 1: Strategic Developments - Huajian Medical has entered into a strategic cooperation framework agreement with BGI CoWin to establish the IVD-BGI CoWin Innovation Drug Intellectual Property Tokenization Fund, which will invest in projects under a NewCo + RWA Web3 exchange ecosystem model [1] - BGI CoWin, initiated by the biotechnology leader BGI Genomics, brings years of investment experience and project resources in the fields of innovative medicine and drugs [1] Group 2: Market Performance - The company's market capitalization has surged from HKD 3.6 billion to nearly HKD 8 billion following a series of strategic actions, including the announcement of a dual primary listing in the U.S. and the launch of a new brand logo [1] - The combination of "stablecoins + medical RWA" has positioned Huajian Medical as a "new species" in the capital market, indicating a transformative approach to traditional medical finance [1] Group 3: Future Prospects - Applications for stablecoin licenses in New York and Hong Kong are ongoing, and the listing on NASDAQ has yet to occur, suggesting potential future growth and expansion opportunities for the company [1] - The strategic maneuvers in July are likened to a surgical operation, aiming to leverage Web3 technology to convert innovative medical drug assets into "digital gold" on the blockchain [1]
港股异动 | 华检医疗(01931)午后涨近13% 半个月内累计涨幅超1.3倍 七大战略行动助推公司市值翻倍